Author: admin

Metastatic Breast Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Metastatic Breast Cancer pipeline landscape. It covers the Metastatic Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Metastatic Breast Cancer Research. Learn more about our innovative pipeline today! @ Metastatic Breast Cancer Pipeline Outlook

 

Key takeaways from the Metastatic Breast Cancer Pipeline Report

  • In January 2025:- Oncolytics Biotech:- The purpose of this study is to find out the possible anti-cancer effect of pelareorep in combination with chemotherapy [paclitaxel] and avelumab in treating a type of breast cancer called Hormone Receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 negative(HER2-) breast cancer, which is either locally advanced or has metastasized (cancer that has spread in your body). The study will investigate if pelareorep in combination with paclitaxel and avelumab is more effective than paclitaxel alone, or pelareorep and paclitaxel. The safety of the combination treatments will also be evaluated.
  • In January 2025:- Eli Lilly and Company:- The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.
  • In January 2025:- Allarity Therapeutics:- The Phase 2 study is using 2x-121 DRP® biomarker in metastatic breast cancer patients to identify patients likely to respond to and benefit from treatment with 2X-121. 2X-121 is a small molecule targeted inhibitor of Poly ADP ribose polymerase (PARP), a key enzyme involved in DNA damage repair in cancer cells. The PARP inhibitor demonstrated clinical activity in a prior Phase 1 study in a number of solid tumors. 2X-121 has a novel dual-inhibitory action against both PARP 1/2 and Tankyrase 1/2. The molecule is also active in P-glycoprotein expressing cells, suggesting it may overcome some of the PARP inhibitor resistance.
  • DelveInsight’s Metastatic Breast Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Metastatic Breast Cancer treatment.
  • The leading Metastatic Breast Cancer Companies working in the market include Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, GlycoMimetics Incorporated, Rhizen Pharmaceuticals SA, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd., Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Jiangsu Hengrui Medicine Co., Tyme, Inc., Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., and Taizhou Hanzhong biomedical co. Ltd, and others.
  • Promising Metastatic Breast Cancer therapies in the various stages of development include Tucatinib, Capecitabine, Trastuzumab, Palifosfamide, Bavituximab, NK105, Paclitaxel, Navelbine, Herceptin, and others

 

Stay informed about the cutting-edge advancements in Metastatic Breast Cancer treatments. Download for updates and be a part of the revolution in care @ Metastatic Breast Cancer Clinical Trials Assessment

 

Metastatic Breast Cancer Emerging Drugs Profile

  • Giredestrant: Roche

Giredestrant is a next generation investigational Selective estrogen receptor degrader (SERD), designed to fully block ER signalling with robust receptor occupancy. Oestrogen encourages HR-positive breast cancer cells to grow by attaching to the ER. Giredestrant works by blocking this receptor to prevent the action of oestrogen, and in the process causes the receptor to be degraded. This investigational medicine has also shown efficacy regardless of ESR1 mutation status (mutations in the ESR1 gene are important mechanisms of resistance to hormone therapy).

 

  • Disitamab Vedotin: RemeGen

Disitamab Vedotin (RC48) is a novel anti-HER2 antibody-drug conjugate (ADC) which is currently across various solid tumor types. It was the first domestically-developed ADC in China approved by the CDE for clinical development in China. ADCs are a therapeutic modality consisting of an antibody molecule linked to a highly cytotoxic agent, and is typically designed to specifically deliver chemotherapies to tumor cells.

 

  • EndoTAG®-1 (SB05): SynCore Biotechnology

SB05 is an innovative composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. Due to the positively charged lipids, SB05 interacts with newly developing, negatively charged endothelial cells, which are especially required for the growth of tumor blood vessels. The SB05 paclitaxel component attacks the activated endothelial cells as they divide, thus targeting the blood supply to tumors without affecting the supply to not activated endothelial cells of healthy tissue. By doing this, SB05 is expected to prevent the formation of new tumor blood vessels and to inhibit tumor growth.

 

  • Stenoparib (2X-121): Allarity Therapeutics

Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. Given its novel mechanism of action and ability to cross the blood brain barrier (BBB), plus its associated DRP®, stenoparib is poised to yield improved efficacy, lower toxicity, and lower drug resistance compared the other late-stage or marketed PARP inhibitors.

 

Learn more about Metastatic Breast Cancer Drugs opportunities in our groundbreaking Metastatic Breast Cancer Research and development projects @ Metastatic Breast Cancer Unmet Needs

 

Metastatic Breast Cancer Companies

Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, GlycoMimetics Incorporated, Rhizen Pharmaceuticals SA, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd., Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Jiangsu Hengrui Medicine Co., Tyme, Inc., Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., and Taizhou Hanzhong biomedical co. Ltd, and others.

 

Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

 

Metastatic Breast Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Discover the latest advancements in Metastatic Breast Cancer treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Metastatic Breast Cancer Market Drivers and Barriers, and Future Perspectives

 

Scope of the Metastatic Breast Cancer Pipeline Report

  • Coverage- Global
  • Metastatic Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Metastatic Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Metastatic Breast Cancer Companies- Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, GlycoMimetics Incorporated, Rhizen Pharmaceuticals SA, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd., Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Jiangsu Hengrui Medicine Co., Tyme, Inc., Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., and Taizhou Hanzhong biomedical co. Ltd, and others.
  • Metastatic Breast Cancer Therapies- Tucatinib, Capecitabine, Trastuzumab, Palifosfamide, Bavituximab, NK105, Paclitaxel, Navelbine, Herceptin, and others.

 

For a detailed overview of our latest research findings and future plans, read the full details of Metastatic Breast Cancer Pipeline on our website @ Metastatic Breast Cancer Emerging Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic Breast Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic Breast Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Giredestrant: Roche
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Stenoparib – Allarity Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. ARV-471: Arvinas
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Metastatic Breast Cancer Key Companies
  21. Metastatic Breast Cancer Key Products
  22. Metastatic Breast Cancer- Unmet Needs
  23. Metastatic Breast Cancer- Market Drivers and Barriers
  24. Metastatic Breast Cancer- Future Perspectives and Conclusion
  25. Metastatic Breast Cancer Analyst Views
  26. Metastatic Breast Cancer Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/novel-drug-delivery-devices

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Breast Cancer FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

Gold Terra Resources (TSX: YGT.V) Launches 2025 Drilling Program(s) for High-Grade Gold – More Stocks Inside!

Gold Terra Resource Corp. (TSX.V: YGT) (OTCQB: YGTFF) has officially commenced its 2025 wedge hole drilling program, continuing its aggressive exploration of the prolific Campbell Shear (CS) from master hole GTCM24-056 on the Con Mine Option (CMO) Property. The master hole, drilled to a depth of 3,002 metres, will serve as a foundation for multiple wedge offshoots, allowing for an efficient and cost-effective evaluation of the CS at depths up to 600 metres below the Robertson Shaft at 1,900 metres.

Gold Terra Advances Deep Exploration Strategy

The primary objective of this advanced drilling initiative is to test for high-grade gold mineralization in the CS, which has a historic production record of 5.1 Moz at an average grade of 16 g/t (refer to the Oct. 21, 2022, Technical Report). By leveraging wedge drilling, the company aims to unlock new gold ounces at depth while maximizing cost-efficiency compared to traditional surface drilling methods.

The CMO Property, currently under option from a subsidiary of Newmont Corporation, remains 100% acquirable by Gold Terra upon meeting specific conditions outlined in the CMO Property Option Agreement (refer to the Company’s news release dated November 22, 2021). The target zone for the drilling campaign lies between 1,900 and 2,600 metres in elevation, downdip from the historically mined 5.1 Moz deposit, in a steep southward plunge.

Yellowknife Project: A Premier High-Grade Gold Camp

The Yellowknife Project (YP) spans 918 sq. km in the Northwest Territories, strategically positioned near Yellowknife. The company controls one of Canada’s six major high-grade gold camps, leveraging key infrastructure such as roads, air transport, hydroelectric power, and skilled labor. Gold Terra is actively drilling the Campbell Shear, a gold-rich structure with historic production of 14 Moz, including the Con Mine Option (CMO) property, which produced 6.1 Moz (1938-2003). YP and CMO cover 70 km of the Yellowknife greenstone belt, hosting past-producing Con and Giant gold mines.

CEO Gerald Panneton Highlights Expansion Potential

Gold Terra’s Chairman and CEO, Gerald Panneton, emphasized the significance of this drilling initiative: “Building on our success in 2024, we are excited to start the 2025 wedge hole drilling program to assess the high-grade gold potential of the Campbell Shear below the Robertson Shaft. This drilling method is both efficient and cost-effective, allowing us to explore a large, under-explored area 600 to 800 metres below existing infrastructure. Our goal is to continue adding high-grade gold ounces to our upcoming Mineral Resource Estimate (MRE).”

Gold Terra’s Vision for Re-Establishing Yellowknife as a Premier Gold Mining District

Situated within the prolific Yellowknife greenstone belt, the YP and CMO properties cover nearly 70 kilometers of mineralized shear zones, hosting the former-producing Con and Giant gold mines. Gold Terra’s exploration efforts have identified substantial gold mineralization zones, with numerous high-potential targets still awaiting testing. The company remains steadfast in its mission to restore Yellowknife’s status as one of Canada’s top-tier gold mining jurisdictions.

Other High-Growth Stocks Making Waves:

MGO Global, Inc. (MGOL): operates as a lifestyle brand portfolio company, focusing on fashion design, brand development, and management, notably associated with the Messi brand.

NanoVibronix, Inc. (NAOV): is a medical device company specializing in non-invasive biological response-activating devices that target wound healing and pain therapy.

Sacks Parente Golf, Inc. (SPGC): designs and manufactures high-performance golf equipment, including putters and shafts, aiming to enhance player performance through innovative technology.

Power Nickel Inc. (PNPN.V): Hits 52-week highs in Canada and the US today, drawing increased investor interest and continues to expand the Lion Zone and capitalize on rising demand across precious and base metals. Stay tuned for updates as this project progresses and remains a standout in a resilient precious metals market.

With small-cap stocks gaining traction amid growing investor interest in mining, technology and biotech sectors, YGT.V, MGOL, NAOV, SPGC, and PNPN.V are among the stocks to watch as momentum builds.

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gold Terra Resources (TSX: YGT.V) Launches 2025 Drilling Program(s) for High-Grade Gold – More Stocks Inside!

J Weeks Entertainment Presents “Dear Darryl: A Letter to My Father” at Conyers Rockdale Council for the Arts

New Stage Production Explores the Complex Journey from Boyhood to Manhood.

J Weeks Entertainment announces its latest theatrical production, “Dear Darryl: A Letter to My Father,” scheduled for March 14, 15, and 16 at the Conyers Rockdale Council for the Arts. The production aims to bring attention to themes of identity, resilience, and the often-unspoken realities that arise from growing up without a father figure. The show marks an important milestone for J Weeks Entertainment, which has built a reputation for creating impactful stage plays that resonate with diverse audiences.

In this one-act play, the narrative follows the protagonist through three stages of life, capturing moments of innocence, growing confidence, and ultimate perseverance. This progression offers a poignant depiction of how individuals adapt and find strength despite the loss or absence of a father.

The story introduces characters such as Young Weeks (an adolescent representation of J Weeks), J-Rod (the teenage version), and J Weeks (the adult man who confronts his struggles as a father and husband). These perspectives illustrate how the absence of a paternal figure does not define a person’s worth, but rather serves as a catalyst for growth, self-discovery, and finding power in one’s own choices.

The production is set to take place at 910 Center Street Northeast, Conyers, GA 30012, a location known for its commitment to community engagement and the arts. Audience members will be invited to immerse themselves in the lives of characters like Do-Right, a man who once had everything but lost it all, and Quameh Rico, a neighborhood hero grappling with a street-life past while aspiring to build a new legacy through business. Through these intertwined stories, “Dear Darryl: A Letter to My Father” underscores the universal quest for acceptance, the importance of confronting unresolved trauma, and the journey from boyhood to manhood.

“A boy does what he wants to do… A man does what he has to do,” commented J Weeks, reflecting on the play’s deeper message of responsibility and growth. J Weeks Entertainment was established in 2010 to provide grassroots artists with a platform for creative expression. Its theatrical productions seek to empower audiences and raise social awareness, consistently delivering thought-provoking performances that spark meaningful conversations in the community.

Tickets for “Dear Darryl: A Letter to My Father” are available through Eventbrite at https://www.eventbrite.com/e/dear-darryl-stage-play-tickets-1218690148039?aff=oddtdtcreator. Media outlets are encouraged to cover this event to help foster wider discussions about identity, resilience, and the responsibilities that come with stepping into adulthood. Interviews and press opportunities are available upon request.

For more information on J Weeks Entertainment visit https://www.jweeksentertainment.com.

About J Weeks Entertainment

J Weeks Entertainment was created in 2010 to offer grassroots artists a space to showcase their talents through theater and the arts. By focusing on real-life issues that resonate with the community, the company uses the stage as a platform to inspire, encourage thoughtful reflection, and ignite transformative change.

Media Contact
Company Name: J Weeks Entertainment
Contact Person: J Weeks
Email: Send Email
Phone: 301-846-8580
Country: United States
Website: https://www.jweeksentertainment.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: J Weeks Entertainment Presents “Dear Darryl: A Letter to My Father” at Conyers Rockdale Council for the Arts

The UK Data Center Market Research Analysis 2030: Get Insights on 227 Existing Data Centers & 39 Upcoming Facilities – Arizton

“UK Data Center Market Research Report by Arizton”

 

According to Arizton’s latest research report, the United Kingdom data center market is growing at a CAGR of 13.33% during 2025-2030.

     

Looking for More Information? Click: https://www.arizton.com/market-reports/uk-data-center-market-investment-analysis

 

Report Scope:     

Market Size – Investment (2030): $22.65 Billion         

Market Size – Area (2030): 2.19 Million Sq. Ft.

Market Size – Power Capacity (2030): 462 MW

CAGR – Investment (2024-2030): 13.33%    

Colocation Market Size – Revenue (2030): $8.84 Billion

Historic Year: 2021-2023             

Base Year: 2024           

Forecast Year: 2025-2030             

     

UK Data Center Market Overview

The UK is emerging as a leading hub for data center investments in Europe, driven by the increasing adoption of cloud services, rising internet penetration, and strong government support. Significant investments are being made by both local and international data center providers, including hyperscale operators like AWS, Microsoft, Google, and others, who are establishing new cloud regions in the country. The UK’s data protection laws, such as the Data Protection Act and GDPR, have further encouraged local data storage compliance, boosting data center growth.

Key developments include large-scale investments in infrastructure, like AWS’s planned $10.45 billion investment in data centers over the next five years, and Google’s $1 billion investment in a new data center in Waltham Cross. There are also notable partnerships, such as Vodafone and Microsoft’s $1.5 billion collaboration to enhance cloud services and AI.

The UK’s connectivity is bolstered by 56 existing submarine cables, with new cables like the Beaufort and IOEMA cables set to expand global connectivity. Additionally, the government is focused on enhancing broadband infrastructure and supporting digital access nationwide.

Technological advancements, particularly in AI, IoT, big data, and 5G networks, are driving demand for data centers, as is the rapid growth of mobile and social media use. These trends are accelerating the digital transformation across sectors such as healthcare, finance, and government, positioning the UK as a major player in the data center market.

 

The UK Pioneers Renewable Energy and Data Center Growth

The UK is progressing towards generating 95% of its electricity from renewables by 2030, with 43% of energy already sourced from renewables as of September 2024. London aims for over 15% renewable energy by 2030 to support its carbon neutrality target by 2050. This renewable shift is fostering the growth of data centers, as companies adopt sustainable energy solutions. Notable examples include Amazon’s deal to acquire 159 MW of energy from the East Anglia Three offshore wind farm, and Iron Mountain’s plan to source 5 MW of rooftop solar for its LON-1 data center.

The demand for renewable power is driving the expansion of data centers across the country, with major projects like VIRTUS Data Centres, DC01UK, and Kao Data developing facilities with significant IT capacities. These efforts, alongside grid improvements by Octopus Energy and Global Switch, support the UK’s dual goals of sustainability and enhanced digital infrastructure.

 

Growth of Colocation Data Centers in the UK

The UK is a prominent hub for colocation data centers in Europe, with a strong concentration of facilities, particularly in London. Major operators like Digital Realty, Equinix, CyrusOne, and Telehouse are key players in the market, and the growing demand for cloud services and the expansion of hyperscale operations are expected to significantly increase colocation capacity in the coming years. In recent times, several companies have made substantial investments to develop new data centers across the country. Notable examples include major US-based firms, which have poured billions into the UK’s data center infrastructure. The demand for colocation services is primarily driven by the cloud and IT sectors, with additional interest from industries like banking, finance, and government. While the high-end colocation market continues to grow, the lower-end segment, offering smaller-scale services, is expected to shrink as consolidation within the industry progresses.

 

London: A Prime Hub for Data Center Development

London is a major hub for data center development in the UK, driven by its strong financial sector, dynamic digital economy, and advanced infrastructure. With more than 50 data center facilities in the city, London hosts leading providers like Digital Realty, Equinix, and CyrusOne, catering to sectors like finance, media, and entertainment. The city’s adoption of cloud-based services and advanced technologies such as AI, big data, and IoT continues to accelerate.

In 2024, London saw the development of around 22 new data centers, mostly in the colocation sector. Key investors like VIRTUS Data Centres, Vantage Data Centers, and Echelon Data Centres are contributing to this growth. Notable initiatives include Queen Mary University of London’s collaboration with Schneider Electric to implement a heat recovery system, repurposing waste heat for campus buildings. The city is also exploring supercomputing technologies, with plans to deploy Nvidia GPUs in data centers.

 

Why Should You Buy this Research?

  • Market size available in the investment, area, power capacity, and UK colocation market revenue.
  • An assessment of the data center investment in the UK by colocation, hyperscale, and enterprise operators.
  • Data center investments in the area (square feet) and power capacity (MW) across counties in the country.
  • A detailed study of the existing UK data center market landscape, an in-depth industry analysis, and insightful predictions about the UK data center market size during the forecast period.
  • Snapshot of existing and upcoming third-party data center facilities in the UK
  • Facilities Covered (Existing): 227
  • Facilities Identified (Upcoming): 39
  • Coverage: 34+ Counties
  • Existing vs. Upcoming (Data Center Area)
  • Existing vs. Upcoming (IT Load Capacity)
  • Data center colocation market in the UK
  • Colocation Market Revenue & Forecast (2021-2030)
  • Retail vs Wholesale Colocation Market Revenue & Forecast (2021-2030)
  • Retail & Wholesale Colocation Pricing
  • The UK data center landscape market investments are classified into IT, power, cooling, and general construction services with sizing and forecast.
  • A comprehensive analysis of the latest trends, growth rate, potential opportunities, growth restraints, and prospects for the industry.
  • Business overview and product offerings of prominent IT infrastructure providers, construction contractors, support infrastructure providers, and investors operating in the industry.
  • A transparent research methodology and analysis of the demand and supply aspects of the industry.

 

Book the Free Sample Now: https://www.arizton.com/market-reports/uk-data-center-market-investment-analysis

 

The Report Includes the Investment in the Following Areas:

IT Infrastructure

  • Servers
  • Storage Systems
  • Network Infrastructure

 

Electrical Infrastructure

  • UPS Systems
  • Generators
  • Transfer Switches & Switchgears
  • PDUs
  • Other Electrical Infrastructure

 

Mechanical Infrastructure

  • Cooling Systems
  • Rack Cabinets
  • Other Mechanical Infrastructure

 

Cooling Systems

  • CRAC & CRAH Units
  • Chiller Units
  • Cooling Towers, Condensers & Dry Coolers
  • Other Cooling Units

 

General Construction

  • Core & Shell Development
  • Installation & Commissioning Services
  • Engineering & Building Design
  • Fire Detection & Suppression Systems
  • Physical Security
  • Data Center Infrastructure Management (DCIM)

 

Tier Standard

  • Tier I & Tier II
  • Tier III
  • Tier IV

 

Geography

  • Greater London
  • Other Counties

 

Vendor Landscape

IT Infrastructure Providers

  • Arista Networks
  • Atos
  • Broadcom
  • Cisco Systems
  • Dell Technologies
  • Fujitsu
  • Hewlett Packard Enterprise
  • Huawei Technologies
  • IBM
  • Juniper Networks
  • NetApp

 

Data Center Construction Contractors & Sub-Contractors

  • 2bm
  • AECOM
  • Arup
  • ARC:MC
  • AtkinsRéalis
  • BladeRoom Data Centres
  • Bouygues Construction
  • Deerns
  • Future-tech
  • HDR Architecture
  • INFINITI IT
  • ISG
  • JCA Engineering
  • Kirby Group Engineering
  • ACIES Civil and Structural
  • Mace Group
  • Mercury
  • MiCiM
  • StudioNWA
  • Sweet Projects
  • RED Engineering Design
  • SPIE
  • Skanska
  • STO Building Group
  • Sudlows
  • TTSP
  • Waldeck

 

Support Infrastructure Providers

  • ABB
  • Airedale
  • Caterpillar
  • Cummins
  • Delta Electronics
  • Eaton
  • Kohler
  • Legrand
  • Mitsubishi Electric
  • Pillar Power Systems
  • Rittal
  • Rolls-Royce
  • Riello Elettronica Group
  • Schneider Electric
  • Siemens
  • Socomec
  • STULZ
  • Vertiv
  • AF Switchgear
  • AVK

Data Center Investors

  • Amazon Web Services
  • Ark Data Centres
  • Colt Data Centre Services
  • CyrusOne
  • Datum
  • Digital Realty
  • Echelon Data Centres
  • Equinix
  • Global Switch
  • Google
  • Green Mountain
  • Iron Mountain
  • Kao Data
  • Microsoft
  • nLighten
  • NTT DATA
  • Pure Data Centres
  • Telehouse
  • Vantage Data Centers
  • VIRTUS Data Centres
  • Yondr Group

 

New Entrants

  • Ada Infrastructure
  • CloudHQ
  • Digital Reef
  • Global Technical Realty
  • Humber Tech Park
  • J Mould Reading
  • SEGRO
  • Latos
  • QTS Data Centers
  • EdgeNebula

 

Key Questions Answered in the Report:     

How many existing and upcoming data center facilities exist in the UK?

How big is the UK data center market?

How much MW of power capacity will be added across the UK during 2025-2030?

What factors are driving the UK data center market?

Who are the key investors in the UK data center market?

   

Check Out Some of the Top Selling Research Reports:   

Spain Data Center Market – Investment Analysis & Growth Opportunities 2025-2030

https://www.arizton.com/market-reports/spain-data-center-market-investment-analysis-report

Germany Data Center Market – Investment Analysis & Growth Opportunities 2024-2029

https://www.arizton.com/market-reports/germany-data-center-market-2025

 

Why Arizton?                                              

100% Customer Satisfaction                                              

24×7 availability – we are always there when you need us                                              

200+ Fortune 500 Companies trust Arizton’s report                                              

80% of our reports are exclusive and first in the industry                                              

100% more data and analysis                                              

1500+ reports published till date                            

                 

Post-Purchase Benefit                                          

  • 1hr of free analyst discussion                                          
  • 10% off on customization                       

                

About Us:                                                                                   

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/uk-data-center-market-investment-analysis

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The UK Data Center Market Research Analysis 2030: Get Insights on 227 Existing Data Centers & 39 Upcoming Facilities – Arizton

T-Cell Acute Lymphoblastic Leukemia FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

DelveInsight’s, “T-Cell Acute Lymphoblastic Leukemia Pipeline Insight” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in T-Cell Acute Lymphoblastic Leukemia pipeline landscape. It covers the T-Cell Acute Lymphoblastic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the T-Cell Acute Lymphoblastic Leukemia Treatment Landscape. Click here to read more @ T-Cell Acute Lymphoblastic Leukemia Pipeline Outlook

 

Key Takeaways from the T-Cell Acute Lymphoblastic Leukemia Pipeline Report

  • In January 2025:- Beam Therapeutics Inc.:– This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to < 12 years), and a Phase 2 cohort.
  • DelveInsight’s T-Cell Acute Lymphoblastic Leukemia pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for T-Cell Acute Lymphoblastic Leukemia treatment.
  • The leading T-Cell Acute Lymphoblastic Leukemia Companies such as Ascentawits Pharmaceuticals, Wugen, Jazz Pharmaceuticals, iCellGene Therapeutics, HebeiSenlangBiotechnology, Nanjing Bioheng Biotech, and others.
  • Promising T-Cell Acute Lymphoblastic Leukemia Therapies such as WU-CART-007, LY3039478, Dexamethasone, Vincristine, Daunorubicin, and others.

 

Stay informed about the cutting-edge advancements in T-Cell Acute Lymphoblastic Leukemia treatments. Download for updates and be a part of the revolution in cancer care @ T-Cell Acute Lymphoblastic Leukemia Clinical Trials Assessment

 

T-Cell Acute Lymphoblastic Leukemia Emerging Drugs Profile

 

  • AST-3424: Ascentawits Pharmaceuticals

AST-3424 is a first-in-class small molecule coupled targeted drug developed by the Aixindawei R&D team that relies on AKR1C3 enzyme activation. It selectively cleaves the aldehyde-keto reductase family 1 member C3 (AKR1C3) into a cytotoxic active form (AST-2660). The diaziridine (AST-2660) released by AST-3424 is similar to the standard chemotherapy drugs thiotepa and mitomycin C, which alkylates and cross-links DNA at the N7 (or O6) position of guanine, leading to cell death. SWOG was commissioned by the National Cancer Institute (NCI) to conduct a Phase II clinical study of relapsed and refractory T-ALL. The Phase II clinical study of relapsed and refractory T-ALL is a single-arm, open-label, OBI-3424 monotherapy (one treatment cycle every 21 days, with administration on the 1st and 8th days) led by SWOG (Southwest Oncology Group) with the National Cancer Institute as the main sponsor. The commercial rights for AST-3424 outside of Asia belong to the company’s global partner OBI. Currently, the drug is in Phase II stage of its development for the treatment of T-ALL.

 

  • WU-CART-007: Wugen

WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies. WU-CART-007 is manufactured using healthy donor-derived T-cells to eliminate the risk of malignant cell contamination historically observed in the autologous CAR-T setting. WU-CART-007 is currently being evaluated in a global Phase I/II clinical trial for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL). WU-CART-007 has received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the U.S. Food and Drug Administration for the treatment of R/R T-ALL/LBL.

 

Learn more about T-Cell Acute Lymphoblastic Leukemia Drugs opportunities in our groundbreaking Melanoma research and development projects @ T-Cell Acute Lymphoblastic Leukemia Unmet Needs

 

T-Cell Acute Lymphoblastic Leukemia Companies

Ascentawits Pharmaceuticals, Wugen, Jazz Pharmaceuticals, iCellGene Therapeutics, HebeiSenlangBiotechnology, Nanjing Bioheng Biotech, and others.

 

T-Cell Acute Lymphoblastic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

T-Cell Acute Lymphoblastic Leukemia Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Discover the latest advancements in T-Cell Acute Lymphoblastic Leukemia treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ T-Cell Acute Lymphoblastic Leukemia Market Drivers and Barriers, and Future Perspectives

 

Scope of the T-Cell Acute Lymphoblastic Leukemia Pipeline Report

  • Coverage- Global
  • T-Cell Acute Lymphoblastic Leukemia Companies- Ascentawits Pharmaceuticals, Wugen, Jazz Pharmaceuticals, iCellGene Therapeutics, HebeiSenlangBiotechnology, Nanjing Bioheng Biotech, and others.
  • T-Cell Acute Lymphoblastic Leukemia Therapies- WU-CART-007, LY3039478, Dexamethasone, Vincristine, Daunorubicin, and others.
  • T-Cell Acute Lymphoblastic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • T-Cell Acute Lymphoblastic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of T-Cell Acute Lymphoblastic Leukemia Pipeline on our website @ T-Cell Acute Lymphoblastic Leukemia Emerging Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. T-Cell Acute Lymphoblastic Leukemia: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Drug Name: Company Name
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. AST-3424: Ascentawits Pharmaceuticals
  11. Drug profiles in the detailed report…..
  12. Early stage products (Phase I)
  13. WU-CART-007: Wugen
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. T-Cell Acute Lymphoblastic Leukemia Key Companies
  17. T-Cell Acute Lymphoblastic Leukemia Key Products
  18. T-Cell Acute Lymphoblastic Leukemia- Unmet Needs
  19. T-Cell Acute Lymphoblastic Leukemia- Market Drivers and Barriers
  20. T-Cell Acute Lymphoblastic Leukemia- Future Perspectives and Conclusion
  21. T-Cell Acute Lymphoblastic Leukemia Analyst Views
  22. T-Cell Acute Lymphoblastic Leukemia Key Companies
  23. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: T-Cell Acute Lymphoblastic Leukemia FDA Approvals, Clinical Trials Assessment, Pipeline Insights and Companies | DelveInsight

B2B Digital Payment Market Recent Trends, Outlook, Size, Share, Top Companies, Industry Analysis, Future Development & Forecast – 2028

“PayPal (US), Fiserv (US), FIS (US), Global Payments (US), ACI Worldwide (US), Block (US), MasterCard (US), Visa (US), Payoneer (US), Stripe (US), Helcim (Canada), Payset (UK), Paytm (India), Razorpay (India), Rapyd (UK).”
B2B Digital Payment Market by Offering (Solutions, Services), Payment Method (Credit Cards/Debit Cards/Virtual Cards, Digital Wallet), Transaction Type (Domestic, Cross-Border), Vertical and Region – Global Forecast to 2028.

The B2B digital payment market is expected to expand from USD 4.2 billion in 2023 to USD 8.2 billion by 2028, reflecting a CAGR of 14.3% over the forecast period. These digital payment solutions provide a quicker and more efficient alternative to conventional paper-based transactions. By leveraging electronic payments, businesses can streamline processing, minimize manual errors, and reduce administrative costs linked to traditional checks and invoices.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=254915304

Based on offering, the solutions segment holds the largest market size during the forecast period

The solutions segment of the digital payment market has been classified into payment infrastructure, billing and accounting management, and security, compliance, and fraud prevention management. Major B2B digital payment vendors are gradually adopting smart technologies, such as cloud computing, analytics, and big data, to offer comprehensive solutions to potential customers.

Based on solutions, the billing and accounting management segment is expected to grow with the highest CAGR during the forecast period

Billing and accounting management solutions are integral in the B2B digital payment market, streamlining financial processes, reducing errors, and enhancing overall financial management for businesses. These solutions encompass features like invoicing, payment processing, automated reminders, and expense tracking. They facilitate efficient creation and tracking of invoices, offer diverse payment methods, and provide automated reminders for overdue payments. The ability to categorize expenses, generate comprehensive financial reports, and integrate with accounting software ensures accurate financial insights. Security measures and compliance with regulations safeguard sensitive data, while streamlined approval processes and scalability accommodate diverse business needs. Ultimately, these solutions play a pivotal role in optimizing financial operations, promoting transparency, and supporting informed decision-making in the B2B digital payment landscape.

North America is expected to have the largest market size during the forecast period.

The B2B digital payment market in North America is highly competitive, as the US and Canada have a strong focus on Research and Development (R&D) and innovation. North America has been a global innovator, constantly at the forefront of payment technology along with retail and financial services. The region has always been dependent on the stability and convenience of its well-established payment infrastructure. The widespread adoption of mobile devices, such as smartphones and tablets, and the need to have convenient access to financial solutions have positively affected the B2B digital payment market in North America. The shift from paper-based processes to digital solutions, including digital wallets and virtual cards, was enhancing efficiency and security. Mobile payments gained traction, while blockchain and cryptocurrencies were explored for potential disruption.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=254915304

Unique Features in the B2B Digital Payment Market

B2B digital payments incorporate advanced security measures such as encryption, tokenization, and multi-factor authentication to safeguard transactions. AI-driven fraud detection systems help identify and mitigate fraudulent activities in real-time, ensuring secure transactions.

Unlike traditional payment methods, digital B2B transactions are processed almost instantly, reducing settlement times from days to mere hours or minutes. This leads to improved cash flow management and enhanced business efficiency.

Automation in digital payments minimizes manual intervention by integrating with enterprise resource planning (ERP) and accounting systems. This streamlines invoice processing, reconciliation, and payment approvals, reducing human errors and administrative burdens.

Businesses can access a variety of digital payment methods, including ACH transfers, virtual cards, digital wallets, and blockchain-based payments. This flexibility allows companies to choose the most suitable option based on their transaction needs.

B2B digital payment solutions facilitate seamless international transactions by supporting multiple currencies and complying with global financial regulations. They help businesses reduce foreign exchange risks and transaction costs associated with cross-border payments.

Major Highlights of the B2B Digital Payment Market

Businesses are moving away from traditional paper-based transactions such as checks and invoices toward digital solutions. The adoption of electronic payments reduces processing time, minimizes errors, and enhances overall operational efficiency.

AI-powered automation and blockchain technology are revolutionizing the B2B payment landscape. AI improves fraud detection and workflow automation, while blockchain ensures secure, transparent, and immutable transactions, particularly for cross-border payments.

With globalization, businesses require seamless international payment solutions. Digital B2B payments offer multi-currency support, compliance with international regulations, and reduced transaction costs, making cross-border transactions more efficient.

B2B digital payment solutions are increasingly integrated with ERP, accounting, and financial management systems. This connectivity streamlines invoice reconciliation, cash flow management, and reporting, enabling businesses to maintain better financial control.

Security remains a top priority, with businesses implementing encryption, multi-factor authentication, and AI-driven fraud detection. These measures help prevent unauthorized transactions and ensure compliance with regulatory standards.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=254915304

Top Companies in the B2B Digital Payment Market

Various globally established players, such as PayPal (US), Fiserv (US), FIS (US), Global Payments (US), ACI Worldwide (US), Block (US), MasterCard (US), Visa (US), Payoneer (US), Stripe (US), are dominating the B2B digital payment market. To increase their market share in the B2B digital payment market, these competitors have used a variety of growth methods, including partnerships, agreements, collaborations, new product releases, product enhancements, and acquisitions.

PayPal has established itself as a prominent player in the B2B digital payment market, offering a range of services tailored to businesses. Its services include business accounts, invoicing, checkout integration, debit cards, working capital loans, and a commerce platform. While traditionally associated with consumer transactions, PayPal has made efforts to cater to businesses’ needs for online and in-person payments. With features like customizable invoicing, PayPal Checkout for online payments, and the convenience of in-person transactions through PayPal Here, businesses can seamlessly manage their revenue streams. PayPal’s comprehensive reporting tools aid in tracking finances, while its integration options and APIs empower businesses to embed payment functionalities into their platforms. Moreover, the PayPal Commerce Platform encompasses an array of services catering to different business sizes, spanning payment processing to subscription management.

Fiserv is a leading global financial technology company. It specializes in providing a comprehensive range of solutions and services to diverse segments of the financial industry. Fiserv’s core areas of expertise encompass payment and processing solutions, financial services technology, digital banking, risk and compliance solutions, and wealth management. The company is recognized for its commitment to innovation, continually advancing technology to meet the evolving needs of financial institutions and businesses. Through strategic acquisitions and a strong focus on research and development, Fiserv has solidified its position as a key player in shaping the landscape of financial technology. Fiserv excels in delivering technology-driven answers that cater precisely to businesses’ payment requisites, spanning the spectrum from small enterprises to expansive corporations.

FIS (Fidelity National Information Services): FIS is an American multinational company specializing in financial services technology. Headquartered in Jacksonville, Florida, FIS offers a broad range of financial software and services to banks, credit unions, asset managers, and other financial institutions worldwide. The company’s solutions include core banking systems, payment processing, risk management, and digital banking platforms. FIS is known for its expertise in providing technology solutions that help financial institutions streamline operations, enhance customer experiences, and manage regulatory compliance effectively.

Global Payments Inc.: Global Payments is a leading worldwide provider of payment technology and software solutions headquartered in Atlanta, Georgia, USA. Founded in 2000, the company offers a comprehensive suite of payment processing services, including credit and debit card processing, electronic check conversion, and merchant services. Global Payments serves a diverse range of industries, including retail, hospitality, healthcare, and e-commerce, enabling businesses to accept payments securely and efficiently. The company also provides integrated software solutions for managing payments, fraud prevention, and customer engagement, making it a key player in the global payments industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/b2b-digital-payment-market-254915304.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: B2B Digital Payment Market Recent Trends, Outlook, Size, Share, Top Companies, Industry Analysis, Future Development & Forecast – 2028

Art Installation “Cybernetic Existentialism” by Ruffo Caselli Debuts in Genoa, Italy

Historic Promotrice Belle Arti Liguria Gallery Hosts Month-Long Retrospective of Pioneering Artist.

The exhibition “Cybernetic Existentialism” by Ruffo Caselli, recognized as a pioneering figure of this artistic movement, will be inaugurated in Genoa, Italy. Caselli’s works (1932 Florence – 2020 Ovada) will be presented in the city for the first time, following notable displays in Russian fine art museums and his hometown of Milan. The Promotrice Belle Arti Liguria gallery on Via degli Archi 39r will host this month-long retrospective throughout March. The collaboration among Promotrice Belle Arti Liguria, San Donato Gallery, and the Center for the Multidisciplinary Study of Cybernetic Existentialism underscores Caselli’s enduring influence.

Dr. Mario Moneta, director of the gallery founded in 1848 by H.R.H. Prince Carlo Alberto, expresses enthusiasm for the exhibition’s arrival. He notes that the core objective of the institution is to promote art, and this show provides an exceptional occasion to examine how Caselli foresaw and interpreted concepts of digitalization and global interconnectedness. Caselli’s art combines subtle irony with refined elegance, reflecting both the aspirations and anxieties of modern society. Dr. Moneta observes that the artist’s warning against losing human identity in a fast-paced and isolating reality remains relevant today.

An avid experimenter with various media, Caselli integrated painting, drawing, and collage to interrogate the interface between man and machine. Driven by an unwavering curiosity, he forged cross-disciplinary collaborations with philosophers and scientists, creating a body of work that resonates with present-day discussions on artificial intelligence. This Genoa exhibition does more than celebrate the artist’s achievements; it also underscores the urgency of his warnings for a society that must grapple with technology’s profound impact on human identity and collective consciousness.

Caselli’s work invites viewers to engage in existential introspection, with each piece prompting reflection on the essence of humanity. Through understated irony, his art depicts a world where machines and humans grow ever more alike, moving from humanoids to hybrids and culminating in figures nearly indistinguishable from robots. Strategically placed images and philosophical motifs convey the mechanization of humans and the humanization of machines in a manner that intrigues international audiences. Since the early 1980s, Caselli’s pieces have captivated observers at various cultural centers in the United States. Now, these groundbreaking works will enrich the cultural dialogue in Genoa and contribute to ongoing discussions surrounding Cybernetic Existentialism.

For more information visit http://www.promotricebellearti.org and https://www.cyberneticexistentialism.com.

About Promotrice Belle Arti Liguria

Promotrice Belle Arti Liguria is a historic gallery in Genoa dedicated to fostering the appreciation of fine art. Established in 1848, it has maintained a commitment to showcasing the work of both established and emerging artists from around the world.

Media Contact
Company Name: Promotrice Belle Arti Liguria
Contact Person: Dr. Mario Moneta
Email: Send Email
Country: Italy
Website: http://www.promotricebellearti.org

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Art Installation “Cybernetic Existentialism” by Ruffo Caselli Debuts in Genoa, Italy

c-MET NSCLC FDA Approvals, Clinical Trials Assessment, Pipeline Insights, and Companies | DelveInsight

DelveInsight’s, “C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Pipeline Insight” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in C-MET Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the c-MET-NSCLC Treatment Landscape. Click here to read more @ c-MET-NSCLC Pipeline Outlook

 

Key Takeaways from the c-MET-NSCLC Pipeline Report

  • In January 2025:- AbbVie:- A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
  • DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for c-MET-NSCLC treatment.
  • The leading c-MET-NSCLC Companies such as AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.
  • Promising C-MET NSCLC Therapies such as Glumetinib, Tepotinib, INC280, APL-101 Oral Capsules, MCLA-129, Osimertinib, and others.

 

Stay informed about the cutting-edge advancements in c-MET NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ c-MET NSCLC Clinical Trials Assessment

 

c-MET NSCLC Emerging Drugs Profile

 

  • JNJ-61186372: Janssen Research & Development, LLC

JNJ-6372 is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistant EGFR and MET mutations and amplifications. The production and development of the antibody followed Janssen’s licensing agreement with Genmab for use of its DuoBody technology platform. According to the company, JNJ-6372 is a novel bispecific antibody that has the potential to benefit patients with Exon 20 mutation insertions who often do not respond to currently available oral EGFR-targeted or immune checkpoint inhibitor therapies.

 

  • PLB1001 – Beijing Pearl Biotechnology Limited Liability Company

PLB1001 is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, PLB1001 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.

 

Learn more about c-MET NSCLC Drugs opportunities in our groundbreaking c-MET NSCLC Research and development projects @ c-MET NSCLC Unmet Needs

 

c-MET NSCLC Companies

AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.

 

C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intramuscular
  • Intratumoral
  • Intravenous
  • Molecule Type

 

c-MET NSCLC Products have been categorized under various Molecule types such as

  • Gene therapies
  • Bispecific antibodies
  • Immunotherapies
  • Monoclonal antibodies
  • Small molecules
  • Product Type

 

Discover the latest advancements in c-MET NSCLC treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ c-MET NSCLC Market Drivers and Barriers, and Future Perspectives

 

Scope of the c-MET NSCLC Pipeline Report

  • Coverage- Global
  • c-MET NSCLC Companies- AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, and others.
  • C-MET NSCLC Therapies- Glumetinib, Tepotinib, INC280, APL-101 Oral Capsules, MCLA-129, Osimertinib, and others.
  • c-MET NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • c-MET NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of c-MET NSCLC Pipeline on our website @ c-MET NSCLC Emerging Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Collaboration Deals
  9. Mid Stage Products (Phase II)
  10. Telisotuzumab: AbbVie
  11. PLB1001: Beijing Pearl Biotechnology Limited Liability Company
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. JNJ-61186372: Janssen Research & Development, LLC
  15. Drug profiles in the detailed report…..
  16. Pre-clinical and Discovery Stage Products
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
  20. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Products
  21. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Unmet Needs
  22. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Market Drivers and Barriers
  23. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC)- Future Perspectives and Conclusion
  24. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Analyst Views
  25. C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) Key Companies
  26. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: c-MET NSCLC FDA Approvals, Clinical Trials Assessment, Pipeline Insights, and Companies | DelveInsight

AI Governance Market Latest Trends, Future Outlook, Size, Share, Applications, Advance Technology And Forecast – 2029

“Microsoft (US), IBM (US), SAS Institute (US), DataRobot (UK), and Dataiku (US), Fiddler AI (US), 2021.AI (Denmark), Monitaur (US), Credo AI (US), and Fairly AI (Canada).”
AI Governance Market by Functionality (Model Lifecycle Management, Risk & Compliance, Monitoring & Auditing, Ethics & Responsible AI), Product Type (End-to-end AI Governance Platforms, MLOps & LLMOps Tools, Data Privacy Tools) – Global Forecast to 2029.

The UK is becoming a leading participant in the AI governance market, fueled by rising AI implementation in various industries and the urgent demand for ethical and responsible systems. The market features regulatory strategies tailored to specific sectors, as outlined in the 2023 AI Regulation White Paper, which fosters innovation and maintains public confidence. Sectors like healthcare, finance, and legal services are at the forefront of establishing AI governance frameworks to enhance transparency and fairness.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=176187291

Government initiatives like the USD 104.1 million AI task force and USD 6.2 million allocation for AI assurance development are driving progress in governance tools and standards. The UK’s focus on fostering AI safety and trustworthiness, coupled with investments in supercomputing and AI research, positions it as a global leader in promoting ethical and transparent AI systems. These efforts are shaping a robust ecosystem for AI governance in the country.

Increasing Emphasis on AI Regulation

The UK government’s AI Regulation White Paper launched in 2023 underscores the nation’s commitment to balancing innovation with public trust. The framework advocates a sector-specific approach, allowing industries like healthcare, finance, and legal services to adopt tailored guidelines. For instance, the White Paper promotes voluntary measures for ensuring transparency and fairness in AI applications while keeping statutory regulations as a future possibility. This approach has spurred organizations to proactively adopt AI governance frameworks, creating a significant market opportunity for compliance tools and consultancy services.

Rise of AI Assurance Services

The UK is spearheading the development of an AI Assurance Framework to assess and certify AI systems for transparency, fairness, and accountability. The Centre for Data Ethics and Innovation (CDEI) is central to these efforts, receiving £6 million in funding to advance assurance tools and standards. This trend is increasing the need for third-party AI auditing, with industries like finance and healthcare implementing these strategies to reduce risks and enhance public confidence. For instance, UK financial organizations are progressively utilizing assurance frameworks to address regulatory oversight concerning algorithmic decision-making.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=176187291

Financial Sector Leadership in Governance

The Financial Conduct Authority (FCA) is at the forefront of exploring AI’s role in the UK’s financial ecosystem, emphasizing accountability and compliance. Financial institutions are increasingly investing in governance frameworks to manage risks such as algorithmic bias and automated decision errors. According to a 2023 FCA survey, 65% of UK financial firms are actively implementing AI governance measures. These efforts are supported by initiatives like FCA’s guidelines for fair and transparent algorithmic deployment in customer-facing applications.

Challenges for AI governance Market in the UK

The UK’s sector-specific approach to AI regulation, as outlined in the 2023 AI Regulation White Paper, has led to a fragmented framework. Different sectors, such as healthcare, finance, and legal services, are expected to adopt unique guidelines, creating inconsistencies in implementation. This decentralization can result in confusion for businesses operating across multiple industries, hindering uniform compliance. For instance, a company utilizing AI for both financial and healthcare services may struggle to reconcile divergent governance standards.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/ai-governance-market-176187291.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AI Governance Market Latest Trends, Future Outlook, Size, Share, Applications, Advance Technology And Forecast – 2029

Fitness & Wellness Software Market Size & Share | $133.70 BN Worth Market by 2030 – Arizton

“Fitness & Wellness Software Market Research Report by Arizton”

 

According to Arizton’s latest research report, the fitness & wellness software market is growing at a CAGR of 8.51% during 2024-2030.

     

Looking for More Information? Click: https://www.arizton.com/market-reports/fitness-and-wellness-software-market

 

Report Scope:     

Market Size (2030): $133.70 Billion         

Market Size (2024): $81.90 Billion

CAGR (2024-2030): 8.51%    

Historic Year: 2021-2023             

Base Year: 2024           

Forecast Year: 2025-2030    

Market Segmentation: Type, Age Group, End-User, and Geography

Geographic Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa         

     

Fitness & Wellness Software Market Overview

The market for fitness and wellness software is also being propelled by advancements in artificial intelligence (AI) and machine learning (ML). These technologies enable highly personalized fitness plans, tailored nutrition advice, and real-time performance tracking. AI-driven apps can analyze user data to provide recommendations that adapt over time, ensuring users remain engaged and motivated in achieving their health goals. Additionally, wearables that seamlessly sync with software solutions are enhancing the user experience by providing real-time feedback on physical activity, sleep, and overall wellness.

The growing integration of Internet of Things (IoT) devices is also revolutionizing the fitness industry. IoT-enabled wearables, smart gym equipment, and connected devices allow for a more interactive and data-driven approach to fitness, enabling users to track metrics like heart rate, calories burned, and even muscle recovery. This interconnected ecosystem offers users a more comprehensive view of their health, creating more opportunities for continuous improvement.

As the demand for virtual fitness solutions continues to rise, businesses in the fitness and wellness sector are increasingly adopting software to streamline operations and boost customer engagement. Software tools help fitness centers, gyms, and wellness providers manage memberships, track performance, and enhance the user experience by offering remote classes, personalized coaching, and virtual challenges. This shift towards digital solutions ensures businesses stay competitive while providing a flexible, accessible, and engaging fitness experience for their clients.

 

Recent Companies that are creating buzz in the Fitness & Wellness Software Market

  • Peloton: A leader in the fitness market, Peloton offers high-end fitness equipment and subscription-based virtual workout services. It provides on-demand and live classes, allowing users to participate in immersive fitness sessions from home, making it a dominant player in the virtual fitness space.
  • Fitbit (now part of Google): Fitbit remains a key name in the wearables segment, offering fitness trackers paired with a mobile app that monitors physical activity, sleep, and heart rate. Despite occasional synchronization issues, Fitbit continues to evolve its software to enhance the user experience and maintain its market leadership.
  • MyFitnessPal: This popular mobile app tracks diet and exercise, offering personalized nutrition advice to help users maintain healthy habits. It integrates with various wearables and fitness devices, providing a comprehensive approach to fitness tracking.
  • Trainerize: A software designed for personal trainers, Trainerize allows fitness professionals to create customized workout plans and deliver them to clients remotely. With its focus on virtual training, it has become an essential tool for fitness trainers and enthusiasts alike.

 

North American Fitness & Wellness Software Market to Capture the Largest Share

North America remains at the forefront of delivering personalized and scalable fitness services. The region’s focus on preventive healthcare and the growing trend of home fitness solutions are setting global benchmarks for the fitness industry.

The United States is the largest contributor to the North American market, accounting for over 75% of regional revenue in 2023. The U.S. benefits from a well-established fitness culture, with approximately 39% of adults regularly engaging in physical activities. Furthermore, high consumer spending on health and fitness-related expenses, including gym memberships and fitness apps, drives market growth. Tech giants like Peloton and Fitbit, headquartered in the U.S., are further accelerating innovation and accessibility in the sector.

Canada is also making significant contributions to the market, particularly following the pandemic, with a growing focus on mental and physical well-being. The Canadian government’s initiatives, such as ParticipACTION, which promotes physical activity, and the increasing popularity of fitness apps like Trainerize, are driving rapid adoption of fitness technology.

As the market expands, North America will continue to serve as the innovation hub for the global fitness and wellness software industry, providing consumers with cutting-edge solutions for health management, fitness tracking, and overall well-being.

 

Major Corporate Players Boosting Demand for Fitness & Wellness Software Market

Corporate organizations are increasingly prioritizing employee health and wellness as a strategy to boost productivity and reduce healthcare costs. Fitness & Wellness Software tailored for corporate use allows companies to design, implement, and manage comprehensive wellness programs, including health tracking, activity challenges, mental wellness support, nutrition plans, and integration with wearable devices. These solutions help organizations track program effectiveness and create a healthier work environment.

Key trends include the focus on holistic wellness, gamified employee engagement, and stress management features. Hybrid work environments are also influencing software design, with solutions catering to both on-site and remote employees. Leading examples like Virgin Pulse, Limeade, and Fitbit Health Solutions are paving the way.

While the benefits of improved employee health, increased productivity, and cost savings are clear, challenges like implementation costs, data privacy concerns, and low engagement rates must be addressed. The growing focus on employee well-being is expected to drive further innovation in corporate wellness solutions.

 

Book the Free Sample Now: https://www.arizton.com/market-reports/fitness-and-wellness-software-market

 

Key Company Profiles

  • ABC Fitness Solutions
  • Mindbody
  • Vagaro
  • Virtuagym
  • Zenoti
  • Xplor Technologies
  • Zen Planner
  • ClassPass
  • Trainerize
  • Wodify
  • MyFitnessPal
  • Fitbit
  • Peloton
  • Aaptiv
  • Jefit
  • Nudge Coach
  • Gymie
  • TrainHeroic
  • Tonal
  • Exercism
  • BODYPUMP
  • Sworkit
  • WellnessLiving
  • Fitli
  • TrueCoach
  • Kemtai

 

Market Segmentation

Type

  • Cloud-Based Software
  • Mobile Applications
  • On-Premises Software
  • Others

 

Age-Group

  • Adults
  • Geriatrics
  • Pediatrics

 

End-User

  • Fitness Centers & Health Clubs
  • Corporate Organizations
  • Individuals & Home Users
  • Hospitals & Rehabilitation Centers
  • Educational Institutions
  • Others

 

Geography

 

North America

  • The U.S.
  • Canada

 

APAC

  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Singapore
  • Malaysia
  • The Rest of APAC

 

Europe

  • Germany
  • France
  • Russia
  • The U.K.
  • Norway
  • Denmark
  • Italy
  • Poland
  • Spain
  • The Rest of Europe

 

Latin America

  • Brazil
  • Mexico
  • Argentina

 

Middle East & Africa

  • Saudi Arabia
  • The UAE
  • South Africa

 

Key Questions Answered in the Report:     

How big is the global fitness & wellness software market?

What are the significant trends in the fitness & wellness software market?

Which region dominates the global fitness & wellness software market share?

What is the growth rate of the global fitness & wellness software market?

Who are the key players in the global fitness & wellness software market?

   

Check Out Some of the Top Selling Research Reports:   

U.S. Health & Wellness Spa Market – Focused Insights 2024-2029

https://www.arizton.com/market-reports/united-states-health-and-wellness-spa-market

U.S. Corporate Wellness Market – Industry Outlook & Forecast 2024-2029

https://www.arizton.com/market-reports/us-corporate-wellness-market-analysis-2024

 

Why Arizton?                                              

100% Customer Satisfaction                                              

24×7 availability – we are always there when you need us                                              

200+ Fortune 500 Companies trust Arizton’s report                                              

80% of our reports are exclusive and first in the industry                                              

100% more data and analysis                                              

1500+ reports published till date                            

                 

Post-Purchase Benefit                                          

  • 1hr of free analyst discussion                                          
  • 10% off on customization                       

                

About Us:                                                                                   

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/fitness-and-wellness-software-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fitness & Wellness Software Market Size & Share | $133.70 BN Worth Market by 2030 – Arizton